Allergy-Immunology
Cardiology
Endocrinology
Gastroenterology
General Internal Medicine
Geriatric Medicine
Hematology / Oncology
Hepatology
Hospital Medicine
Immunotherapy
Infectious Diseases
Nephrology / Hypertension
Pulmonary & Critical Care
Rheumatology
Sports Medicine

Bibliography 2001

2004 | 2003 | 2002 | 2001 | 2000 | 1999

  1. Argiris A, Murren JR. Staging and clinical prognostic factors in small cell lung cancer, The Cancer Journal (in press), 2001.

  2. Argiris A, Murren JR. Advances in the chemotherapy for small cell lung cancer. The Cancer Journal, 7:228-235, 2001.

  3. Argiris A, Heald P, Kuzel T et al. Phase II trial of 9-AC in cutaneous T-cell lymphoma, Investigational New Drugs, (in press), 2001.

  4. Bennett CL, Crane JM. Quality improvement efforts in oncology: are we ready to begin? Cancer Invest, 19(1):86-95, 2001.

  5. Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel J. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest, 19(2):107-113, 2001.

  6. Davis TC, Dolan N, Ferreira MR, Tomori C, Green KW, Sipler AM, Bennett CL. The role of inadequate health literacy skills in colorectal cancer screening. Cancer Invest, 19(2): 193-200, 2001.

  7. Benson III AB. Oral eniluracil/5-F for advanced colon and breast carcinomas.
    Oncology 15(suppl): 57-63, 2001.

  8. O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson III A. Fluorouracil modulation in colorectal cancer:lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule. An ECOG/CALGB study. J Clin Oncol, 19:2413-2421, 2001.

  9. Okonkwo A, Musunuri S, Talamonti M, Benson III A, et al. Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncology Reports, 8:497-500, 2001.

  10. Olverira AM, Tazelaar HD, Wentzlaff KA, Kosugi NS, Hai N, Benson III  A,
    Miller DL, Yang P. Familial pulmonary carcinoid tumors. Cancer, 91:2104-2109, 2001.

  11. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Benson III AB, Cummings B, Gunderson L, Macdonald JS. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol, 19:157-163, 2001.

  12. Watanabe T, Wu T, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson III AB, Hamilton SR. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med, 344:1196-1206, 2001.

  13. Blanke CD, Haller DG, Benson AB, Rothenberg ML, Berlin J, Mori M, Hsieh Y-Ch, Miller LL.  A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.  Ann Oncol 12:1575-1580, 2001.

  14. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, Benson AB, Rao S, Joehl RJ.  Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors.  Surgery 130:677-685, 2001.

  15. Bergan R, Waggle DH, Carter SK, Horak I, Slichenmyer W. Tyrosine kinase inhibitors and signal transduction modulators: rationale and current status as chemopreventive agents for prostate cancer, Urology, (in press), 2001.

  16. Bates SE, Kang MH, Dakke S, Meadows B, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T. A phase 1 study of infusional vinblastine in combination with the Pgp antagonist PSC 833 (Valdospar). Cancer, (in press), 2001.

  17. Borko D, Jovanovic BD, Huang S, Liu Y, Naguib KN and Bergan RC. A simple analysis of gene expression and variability in gene arrays based on repeated observations. Amer J Pharmacogenomics, (in press), 2001.

  18. Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S. Phase I study of infusional Paclitaxel in combination with the P-glycoprotein antagonist PSC 833. Journal of Clinical Oncology, 19(3): 832-842, 2001.

  19. Liu YQ, Bergan R. Improved intracellular delivery of oligonucleotides by square wave electroporation, Antisense and Nucleic Acid Drug Development, 11(1), 7-14, 2001.

  20. Liu YQ, Kyle E, Lieberman R, Frausseaue F, Topalian S, Hakim F, Bergan R. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells., Prostate Cancer and Diseases of the Prostate, 4, 1-11, 2001.

  21. Boggio L, Green, D. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. British Journal of Haematology, 112:1-3, 2001.

  22. Gartenhaus RB, Prachand S, Paniaqua M, Li Y, Gordon LI. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clinical Cancer Research, (in press), 2001.

  23. Evens AM and Gartenhaus RB. The potential of arsenic trioxide in combination therapy. In Tallman, MS and Avvisati, G. (Eds): Acute Promyelocytic Leukemia: Toward The Curability of Acute Myeloid Leukemia, Martin Dunitz publishers, (in press), 2001.

  24. Herbert GB, Shi B, Gartenhaus RB. Expression and stabilization of the MCT-1 protein by DNA damaging agents. Oncogene, (in press), 2001.

  25. Nabhan C, Gartenhaus RB, Tallman MS. The role of purine nucleoside analogues and combination therapies in B-cell Chronic Lymphocytic Leukemia. Leukemia, (in press), 2001.

  26. Siegel R, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I associated leukemia/lymphoma. Currrent Treatment Options in Oncology, 2(4):291-300, 2001.

  27. Siegel R, Gartenhaus RB, Kuzel TM. HTLV-1 associated leukemia/lymphoma: epidemiology, biology and treatment. In Sparano JA (Ed): HIV & HTLV- I Associated Malignancies, Kluwer Academic Publishers, (in press), 2001.

  28. Gordon LI. Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and...Bone Marrow Transpl.(in press), 2001.

  29. Czuczman MS, Grillo-Lopez AJ, McLaughlin P, White CA, Saleh M, Gordon LI, LoBuglio AF, Rosenberg J, Alkuzweny B, Maloney DG. Clearing of cells bearing the bcl-2 [t (14; 18)] translocation from blood and marrow of patients treated with Rituximab alone or in combination with CHOP chemotherapy. Annals of Oncology, 12:109-114, 2001.

  30. Gradishar WJ. Clinical status of capecitabine in the treatment of breast cancer. Oncology 15(suppl): S69-S72, 2001.

  31. Westerman MP, Green D, Gilman-Sachs A, Beamen K, Freels S, Boggio L, Allen S, Zuckerman L, Williamson , Schlegel R. Clotting activity in sickle cell trait. Amer J Hematol, (in press), 2001.

  32. Green D.  Genetic hypercoagulability:  should family members be tested?  Blood 98:20, 2001.

  33. Kuzel TM, Kies M, Wu N, Hsieh Y, Rademaker AW. Phase I trial of oral estramustine and 3-hour infusional paclitaxel for the treatment of hormone-refractory prostate cancer. Cancer Investigation, (in press), 2001.

  34. Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, and Kuzel T. Biological correlates of acute hypersensitivity events with DAB389IL-2 (Ontak) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clinical Lymphoma, 1(4):298-302, 2001.

  35. Kim SP, Knight SJ, Tomori BA, Colella KM, Schoor RA, Shih L, Kuzel TM, 
    Nadler RB, and Bennett CL. Health literacy and shared decision  making for prostate cancer patients with low socioeconomic status. Cancer Investigation 19(7): 684-691, 2001.

  36. Kim SP, Schoor RA, Knight SJ, Colella KM, Tennant AG, Shih L, Kuzel TM, Nadler RB, Bennett CL. A pilot study of shared decision making for prostate cancer patients of low socioeconomic status. Cancer Investigation, (in press), 2001.

  37. Knight SJ, Chmiel JS, Sharp LK, Kuzel TM, Nadler RB, Fine R, Moran EM, Sharifi R, Bennett CL. Spouse ratings of quality of life in patients with metastatic prostate cancer of lower socioeconomic status: an assessment of feasibility, reliability and validity. Urology, 57:275-280-2001.

  38. Olsen EA, Duvic M, Martin A, Vonderheid E, Craig F, Cooper K, Stevens S, Kim Y, Frankel A, Wood G, Bowen G, Jegasothy B, Heald P, Gordon M, Pinter-Brown L, Oseroff A, Kuzel TM, et al. Pivotal phase III trial of two dose levels of Denileukin Diftitox for the treatment of mycosis fungoides J Clin Oncol, 19:376-388, 2001.

  39. Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, et al.  The role for interleukin-12 therapy of cutaneous T-cell lymphoma.  Ann N Y Acad Sci 941:177-184, 2001.

  40. Kwaan HC. Abnormalities of hemostasis and fibrinolysis in diabetic patients with emphasis on coronary heart disease. Medicographica, (in press), 2001.

  41. Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Haematologica, 106:52-56, 2001.

  42. Mehta J, Oyama Y, Winter J, Williams S, Tallman MS, Singhal S, Villa M, Shook T, Burt R, Soff G, Masarik S, Gordon L. CD34r cell collection efficiency does not correlate with the preleukapheresis hematocrit. Bone Marrow Transpl, 28:597-601, 2001.

  43. Nabhan C, Mehta J, Tallman MS. The role of bone marrow transplantation in acute promyelocytic leukemia. Bone Marrow Transplantation, 28:219-226, 2001.

  44. Quilitz RE, Arnold AD, Briones GR, Dix SP, Ippoliti C, Kennedy LD, Lucich JL, Mehta J, Peters BG, Tice DS. Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients. Ann Pharmacother, 35:206-216, 2001.

  45. O'Regan RM, Jordan VC. Tamoxifen to raloxifene and beyond, Semin. in Oncol, 28:260-273, 2001.

  46. MacGregor-Schafer J, Lee ES, Dardes R, O'Regan RM, Jordan VC. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY 117018 in tamoxifen-stimulated breast cancer xenografts. Clin Cancer Res, (in press), 2001.

  47. Pasche B. Role of transforming growth factor beta in cancer. Journal of Cellular Physiology, 186:153-168, 2001.

  48. Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, Dobles M, Sorger PK, Murty VVVS, Benezra R. Mad2 haploinsufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature, 409:355-359, 2001.

  49. Gandhi V, Ayres M, Halgren H, Krett NL, Newman R, Rosen ST. Metabolism of 8-Chloro-adenosine in Multiple Myeloma. Cancer Research, (in press), 2001.

  50. Singhal S, Mehta J. Thalidomide in cancer: potential uses and limitations. BioDrugs, (in press) 2001.

  51. Singhal S, Powles R, Mehta J. Blood versus marrow for allogeneic transplantation: long-term follow-up. N Engl J Med, (in press) 2001.

  52. Kantarjian H, Sawyers CL, Hochhausa, Guilhot F, Schiffer C, Niederweiser D, Gambacorti-Passerini C, Stone R, Goldman J, Fischer T, Reiffers J, Miller C, Tallman MS, O'Brien S, Brown R, Silver R, Gratwohl A, Loughran T, Mandelli F, Saglio G, Ottmann O, Lazzarino M, Tura S, Baccarani M, Thiery F, Morra M, Russell N, Zoellner U, Resta D, Capdeville R, Talpaz M, Druker B. Gleevec (imatinib mesylate) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: Results of a phase II study. N Engl J Med, (in press), 2001.

  53. Kini AR, Peterson LC, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood, (in press), 2001.

  54. Lum BL, Advani R, Villena J, Dugan K, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Greenberg PL, Sikic BI. The pharmacokinetics of etoposide and mitoxantrone in a trial of mdr modulation with valspodar (PSC 833) in acute myeloid leukemia. J Clin Oncol, (in press) 2001.

  55. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinhartz P, Sievers E, Coutre S, Dahlberg S, Ellison R, Warrell RP. The U.S. multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J Clin Oncol, (in press), 2001.

  56. Aljandali A, Pollack H, Yeldandi A, Li Y, Weitzman SA, Kamp DW. Asbestos causes apoptosis in alveolar epithelial cells: Role of iron-induced free radicals. J Lab Clin Med, 137:330-9, 2001.

  57. Evron, E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 61:2782-2787, 2001.

  58. Kamp DW, Srinivasan M, Weitzman SA. Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J. Invest Med. 49:68-76, 2001.

  59. Kolli S, Buchmann AM, Williams J, Weitzman SA, Thimmapaya B. Antisense-mediated depletion of p300 in human cells leads to premature G1 exit and up-regulation of c-MYC. Proc Nat Acad Sci USA, 98:4646-4651, 2001.

  60. Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, Weitzman SA, Korz D, Sukamar S. WT1 is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 61:921-925, 2001.

  61. Pecora AL, Lazarus HM, Stadtmauer EA, Winter JN, Van Vliet, Berry D, Gray R, Jennis A, Goldberg S, Cooper B, Preti RA. Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer. Bone Marrow Transpl, 27:1245-1253, 2001

  62. Preti RA, Lazarus H, Winter JN, Stadtmauer E, Nadasi S, McMannis J, Karandish S, Jennis A, Pecora AL. Laboratory and clinical outcomes following tumor cell depiction of peripheral blood progenitor cells using positive and positive/negative selection strategies in breast cancer. Cytotherapy, 3(2):85-96, 2001.